KR20220103980A - Ccr9 억제제 및 항-tnf-알파 차단 항체를 사용하여 ccr9-매개 질환을 치료하는 조성물 및 방법 - Google Patents

Ccr9 억제제 및 항-tnf-알파 차단 항체를 사용하여 ccr9-매개 질환을 치료하는 조성물 및 방법 Download PDF

Info

Publication number
KR20220103980A
KR20220103980A KR1020227019228A KR20227019228A KR20220103980A KR 20220103980 A KR20220103980 A KR 20220103980A KR 1020227019228 A KR1020227019228 A KR 1020227019228A KR 20227019228 A KR20227019228 A KR 20227019228A KR 20220103980 A KR20220103980 A KR 20220103980A
Authority
KR
South Korea
Prior art keywords
ccr9
disease
blocking antibody
tnfα
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020227019228A
Other languages
English (en)
Korean (ko)
Inventor
토마스 샬
제임스 제이. 캠벨
Original Assignee
케모센트릭스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/740,861 external-priority patent/US10792360B1/en
Application filed by 케모센트릭스, 인크. filed Critical 케모센트릭스, 인크.
Publication of KR20220103980A publication Critical patent/KR20220103980A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227019228A 2019-11-21 2020-11-20 Ccr9 억제제 및 항-tnf-알파 차단 항체를 사용하여 ccr9-매개 질환을 치료하는 조성물 및 방법 Abandoned KR20220103980A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962938795P 2019-11-21 2019-11-21
US62/938,795 2019-11-21
US16/740,861 US10792360B1 (en) 2019-11-21 2020-01-13 Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
US16/740,861 2020-01-13
US17/064,550 2020-10-06
US17/064,550 US20210154292A1 (en) 2019-11-21 2020-10-06 Compositions and Methods for Treating CCR9-Mediated Diseases using CCR9 Inhibitor and Anti-TNF-Alpha Blocking Antibodies
PCT/US2020/061569 WO2021102302A1 (en) 2019-11-21 2020-11-20 Compositions and methods for treating ccr9-mediated diseases using ccr9 inhibitor and anti-tnf-alpha blocking antibodies

Publications (1)

Publication Number Publication Date
KR20220103980A true KR20220103980A (ko) 2022-07-25

Family

ID=75974977

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227019228A Abandoned KR20220103980A (ko) 2019-11-21 2020-11-20 Ccr9 억제제 및 항-tnf-알파 차단 항체를 사용하여 ccr9-매개 질환을 치료하는 조성물 및 방법

Country Status (11)

Country Link
US (1) US20210154292A1 (https=)
EP (1) EP4061365A4 (https=)
JP (1) JP2023502267A (https=)
KR (1) KR20220103980A (https=)
CN (1) CN115209896A (https=)
AU (1) AU2020386066A1 (https=)
BR (1) BR112022009638A2 (https=)
CA (1) CA3159127A1 (https=)
IL (1) IL293133A (https=)
MX (1) MX2022006071A (https=)
WO (1) WO2021102302A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI904146B (zh) 2020-03-31 2025-11-11 美商卡默森屈有限公司 使用ｃｃｒ９抑制劑及抗ｉｌ-２３阻斷抗體治療發炎性腸道疾病的組成物及方法
CN116492341B (zh) * 2023-05-19 2025-04-15 广州市红十字会医院 维塞诺在制备治疗白癜风药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ566263A (en) * 2002-05-24 2009-09-25 Millennium Pharm Inc CCR9 inhibitors and methods of use thereof
WO2014088113A1 (en) * 2012-12-04 2014-06-12 Millennium Pharmaceuticals, Inc. Prophylactic or therapeutic method for sjogren's syndrome using specific ccr9 receptor inhibitors/antagonists
DK3126330T3 (en) * 2014-04-04 2019-04-23 Pfizer BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS
WO2016057424A1 (en) * 2014-10-06 2016-04-14 Chemocentryx, Inc. Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
EP3554541B1 (en) * 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US10792360B1 (en) * 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
TWI904146B (zh) * 2020-03-31 2025-11-11 美商卡默森屈有限公司 使用ｃｃｒ９抑制劑及抗ｉｌ-２３阻斷抗體治療發炎性腸道疾病的組成物及方法

Also Published As

Publication number Publication date
IL293133A (en) 2022-07-01
AU2020386066A1 (en) 2022-06-09
CN115209896A (zh) 2022-10-18
MX2022006071A (es) 2022-08-02
EP4061365A4 (en) 2023-11-29
BR112022009638A2 (pt) 2022-08-09
WO2021102302A1 (en) 2021-05-27
JP2023502267A (ja) 2023-01-23
EP4061365A1 (en) 2022-09-28
CA3159127A1 (en) 2021-05-27
US20210154292A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
US11045469B2 (en) Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodies
US10792360B1 (en) Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
US20240100041A1 (en) Compositions and methods for treating inflammatory bowel disease using ccr9 inhibitor and anti-il-23 blocking antibodies
KR20220103980A (ko) Ccr9 억제제 및 항-tnf-알파 차단 항체를 사용하여 ccr9-매개 질환을 치료하는 조성물 및 방법
US20250325662A1 (en) Methods of treating and predicting non-response to anti-tnf treatment in subjects with gastrointestinal tract diseases
RU2846370C1 (ru) Композиции и способы лечения воспалительного заболевания кишечника с применением инибитора CCR9 и блокирующих антител против IL-23
RU2823984C2 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ ИНГИБИТОРАМИ С-С ХЕМОКИНОВОГО РЕЦЕПТОРА 9 (CCR9) И АНТИТЕЛАМИ, БЛОКИРУЮЩИМИ α4β7-ИНТЕГРИН
HK1241891A1 (en) Combination therapy of c-c chemokine receptor-9 (ccr9) inhibitors and anti-alpha4beta7 integrin blocking antibodies for the treatment of inflammatory bowel disease
HK1241891B (en) Combination therapy of c-c chemokine receptor-9 (ccr9) inhibitors and anti-alpha4beta7 integrin blocking antibodies for the treatment of inflammatory bowel disease
BR112017006496B1 (pt) Usos de inibidores de molécula pequena de receptor de c-c quimiocina tipo 9 (ccr9) e anticorpos de bloqueio

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220608

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1902 Submission of document of abandonment before decision of registration